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CHAPTER I
' INTRODUCTION

Six-mercaptopurine is a chemotherapeutic drug which
has been used extensively in clinical research as well as
biological and biochemical experimental studies.
Studies on the absorption, distribution, toxicity and
metabolism of 6-mercaptopurine (6-MP) in experimental animals and in the human have been reported in recent reviews.
The extreme toxicity of 6-MP and its analogs have been
observed in various species.

Phillips (1954) reported that

toxicity occurs in rabbits at a dosage level of 10 to 15 mg/
kg bdy wt/day , while 100 mg/kg bdy wt/day may be required to
produce similar effects in guinea pigs.

According to Hamil-

ton and Elion (1954), toxicity often appears in man at a dosage of 2.5 mg/kg bdy wt/day.

The toxicity of this purine and

its derivatives has imposed obvious limitations in their use
for treatment of leukemia.
Studies in our laboratory during the past year have demonstrated that the chick can tolerate 1200-1800 mg/kg bdy wt/
day of 6-HP .

The writer could find no report of any investi-

gation which involved the chick in regard to the unusual relative high tolerance of this compound, nor any reference to the
metabolic degradation of this purine or its derivatives in
this species.
The present status of research in this area has indicated
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that the therapeutic effectiveness of 6-MP and other purine
derivatives, may be potentiated in man.

It has been estab-

lished that the end product of purine metabolism in man and
in the chick is uric acid, although it is excreted in much
larger amounts in the chick.

In view of the chick's nonnal

high tolerance for 6-MP, it seems logical to assume that
this species may possess a mechanism which enables it to
nonnally detoxify the oxidative metabolic end-products associated wi.th the degradation of 6-MP and other derivatives
more efficiently than man or other previously studied species.
An understanding of the biochemical mechanism responsi-

ble for the chick's capacity to tolerate and efficiently dispose of such agents as 6-MP which are so extremely toxic to
man would contribute significantly to the infonnation now
available for other species.

Such basic information may aid

in the clinical treatment of leukemia, a procedure which ha•
thus far been complicated by the extreme toxicity of 6-MP and
its derivatives.
It is the purpose of this paper to provide a framework of
reference which may be viewed as a segment of a continuing
program directed toward improvement of the effectiveness of
6-MP.

Consequently, in an effort to supplement the informa-

tion necessary prior to the initiation of such studies in the
human, an investigation of the metabolic fate of 6-MP in the
chick was undertaken.

These experiments were designed pri~
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marily to determine the relationship between 6-mercaptopurine toxicity and uri c acid synthesis .

CHAPTER II
REVIEW OF LITERATURE

The preparation of 6-MP was first reported by Elion
et al., (1952) and foi:med part of an investigation of
purine and pyrimidine analogs as potential antimetabolites.
The recognition of its clinical value has led to a large
number of biological and biochemical studies.
A.

Tumor Inhibition
The activity of 6-MP against animal tumors has been

studied vecy extensively.

Clark et al. (1953); Hitchings

and Elion (1954), revealed the ability of 6-MP to suppress
the experimental mouse sarcoma.

The activity of 6-MP

against sarcoma in mice was reported to be potentiated by
azarine (Stock et al., 1955; Clark, 1959}.

Martin et al.,

(1958) reported that a combination of 6-MP and 6-aminonicotinamide markedly augmented the curative effects of X-rays
on adenocarcinoma in mice.

The xanthine oxidase inhibition,

4-hydroxypyrazolo (3,4-d] pyrimidine (HPP) increased the
activity of 6-NP against adenocarcinoma, but the increase
in toxicity was almost as great (Elion et al., 1962).
B.

Anti-leukemic Action
Urethane enhanced the anti-leukemic action of 6-MP in

mice (Marchand and Fujimoto, 1964).

The combination of

6-MP with methylglyoxalbis (guanylhydrazone) was more effective against leukemia in mice than either drug alone (Venditti
et al., 1963).
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c.

Pharmacology
The toxic effects of 6-MP have been described in some

detail (Clark et al., 1953; Phillips et al., 1954).

The

LD50 (single intraperitoneal dose) was about 240 mg/kg in
mice and rats.

The mice died between the 5th and 14th day

after injection, but the rats began to die as early as the
2nd day.

The LD50 for multiple intraperitoneal injections
was 100 mg/kg/day for five days in mice, and about 60 mg/

kg/day for the same period in rats.

The analog was slightly

less toxic when orally administered.
Pathological effects in mice and rats were similar, and
induced hepatic necrosis, hypoplasia of bone marrow, involution of the thymus, and changes in the intestinal epithelium,
such aa edema, congestion, and leucocyte infiltration of the
mucosa in the small intestine.

ln dogs, the drug was about

equally active given intravenously or orally.

Anorexia,

weight loss, vomiting, diarrhea, jaundice, and leukopenia
were observed by Clark et al., 1953; Phillips et al., 1954.
Elion et al., (1954) stated that the radioactivity in
35
the blood of mice injected with 6-MP-s
fell during the
first five hours.

After 24 hrs . very little radioactivity
35
remained in the blood. From 1.5 to 5 hrs. after 6-MP-s
injection into mice, the highest radioactivity was found in
the gut, kidney and liver; smaller amounts were present in
14
the blood, lung, spleen and sternum. Work with c
was also
.
35
used to substantiate the findings using 6-MP-S •
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D.

Metabolism
Six-thiouric acid, formed by the action of xanthine

oxidase, was found to be a non-inhibitory metabolite of
6-MP, in man.
1959).

(Hamilton and Elion , 1954; Loo et al.,

Some of the drug was also converted into organic

sulfate (Hamilton and Elion , 1954).

lt was seen that the

biological activity of 6-MP was increased by the simultaneous administration of the xanthine oxidase inhibitor,
4-hydropyrazolo

3,4-d

pyrimidine (HPP).

This enhance-

ment of activity was correlated by decreased drug catabolism,
thiouric acid and sulfate excretion was diminished, while the
amount of unchanged drug in the urine increased.

Another

metabolite, excreted in the urine of 6-MP-treated rats,
was S-methyl- 6-MP (Elion et al., 1962, 1963).
E.

Clinical Application
The value of 6-MP in the treatment of human cancer was

discussed in detail by various authors, edited by Miner
(1954).

The main application of the drug is in acute leukemia

in children, where it is commonly used sequentially with
hormone and antifolic treatment (Gunz and Dameshek, 1959;
Sutow, 1962).

Patients with chronic granulocytic leukemia

sometines responded to treatment with 6- MP (Southam and
Burchenal, 1959) and its effect was comparable with that of
Myleran (Schullenberger, 1962).

The dose of 6-MP required

for maintenance therapy in this disease was substantially
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reduced by simultaneous administration of 4-hydroxypyrazolo
3,4-d

pyrimidine (HPP), but it does not necessarily mean

that HPP increases the therapeutic effectiveness of the
drug ( Rundles, 1963).
According to Calne (1963), 6-NP was largely ineffective
a gainst most other malignant conditions, although remission
or objective improvement was seen in a significant number
of patients with reticulum cell sarcoma and lymphosarcoma.
Its effectiveness in suppressing i.nu:nune response has led to
the frequent use of 6-MP in kidney transplantation in man.

CHAPTER Ill
MATERIALS AND METHODS

Genetic Stock:

One hundred White Leghorn, day old,

cockerels were used in each of three experiments.

All

experimental animals were obtained from Hy-Lay Hatcheries,
Inc., Bryan, Texas.
The experimental animals were housed in brooders, feed
and water were provided , ad libitum.
Chicks were divided into control and treated groups of
fifty each.

The treated chicks received an average dosage

of 1800 mg/kg bdy wt/day of 6-MP, in gelatin capsules (No.
4) by oral administration.

Initial treatment began at

age 5 days and continued until a lethal dosage (LD50 ) was
observed, between ten and twelve days.
Uric acid determinations on the blood and liver were
made at the following intervals:

(1) 5 days after treatment,

(2) at LD

, and (3) 6-8 days post-treatment.
50
Uric Acid Determination:
I.

Preparation of Samples
A.

Blood
Ten chicks per group were sacrificed by decapi-

tation for each uric acid determination.

Blood from

the cervical vessels was collected by pooling in
centrifuge tubes and allowed to stand at room
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temperature until clotting was completed, then
centrifuged 20 minutes at 2000-2300 rpm.

After

centrifugation, serum was immediately separated
from all solid material (blood cells, etc.).

All

solid material was finally discarded.
B.

Liver
Liver was obtained by excisions after blood

samples had been collected.

It was then frozen

four days, thawed, and homogenized in a Waring
blender with a volume of water equivalent to the
weight of the liver, or the amount required to
obtain a specific dilution factor.

Centrifugation

and separation of serum from solid material (liver
tissue) was identical to that for blood.

All solid

material was discarded.
11.

Colorimetric Method

A,

Principle
The principle of this analysis for serum uric

acid is that of Bittner (1963) in which uric acid
reduces a copper chelate in an acetic acid medium,
eliminating the customary interference from other
reducing substances which occurs in methods employing a carbonate medium and resulting in a highly
specific test for uric acid.

No cyanide was used.
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A trichloracetic acid filtrate or centrifugate
is added to an alcoholic sodium hydroxide solution

to destroy the reducing abilities of certain sulfhydrol compounds and ascorbic acid.

A copper

chelate in acetic acid is t hen added to the alkaline
mixture , and uric acid reduces the cupric complex of
the indicator in a final acid reduction medium.

A

brilliant yel low-orange color develops in less than
ten minutes , and the chromogenic response is stable
for many hours .

The response of the chromogen is

linear through at least 20 mg% using the recollUilended
procedure.

The color developed is read in a colori-

meter or spectrophotometer at or near the wave length
of maximum absorption.
B.

Reagents 1
The reagents for this method are available through

authorized dealers of OXFORD LABORATORIES as OXFORD
URIC ACID REAGENTS, Cat. No. 820 .

The reagent set

contains:
Bittner's Redox Reagent Solution, 8 oz .

This is an

acetic solution of 2, 9-dimethyl - 1, 10-phenanthroline which is complexed with cupric ion.

1obtained commercially from Oxford Laboratories 273
North Shore Boulevard , P.O. Box 5007, San Mateo, California
94402 .
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Alcoholic Sodium Hydroxide, 8 oz.

This is a mix-

ture of half methyl alcohol and half 1.0 N sodium
hydroxide.
Uric Acid Standard Solution, l oz.

This is an aqueous,

slightly acetic, uric acid standard.

Fonnaldehyde is

added as a preservative, and the pH of the solution
is adjusted to 5.5 with glacial acetic acid.

Although

this is packaged as a 25.0 mg% uric acid solution, it
is used as an equivalent of a 5.0 mg% standard in its
final dilution.
Work i n g ~ A£!g Standard Solution.

To a clean 50.0

ml volumetric flask add exactly 1.0 ml of Uric Acid
Standard Solution and 25.0 ml of 5% trichloroacetic
acid.

Fill to the mark with distilled water.

This

solution is stable in plastic at room tEII\perature for
several days.

c.

Procedure
To 1.0 ml of serum 9.0 ml of freshly diluted 5%

trichloroacetic acid (TCA) was added.

The precipita-

ted protein was allowed to remain in the TCA for
fifteen minutes before filtration to assure complete
precipitation.

Wh.at:man No. 40 filter paper was used.

Six alequots per experiment were analyzed.

12
Test tubes were labeled, and reagents were added
as shown:
Unknown
Filtrate ---------------

Standard

Blank

1.0 ml

Working Standard -------

1.0 ml

5% TCA -----------------

0.5 ml

Water------------------

0.5 ml

Alcoholic Sodium
Hydroxide-------------

2.5 ml

2.5 ml

2.5 ml

(Tubes were agitated, allowed to stand about
four minutes, then final reagent was added)

Bittner•s Redox
Reagent---------------

2.5 ml

2.5 ml

2.5 ml

All tubes were mixed and allowed to stand ten
minutes for complete color development.

The color

was stable as compared to the blank for several
hours .

Colorimetric readings were made at 454 mu

using a Bausch & Lomb spectrophotometer.
CALCULATIONS:
l.

Dosage of 6-MP
Dosage Level

= mg/capsule/day

avg. wt. (kg)
mg/capsule/day= avg. wt. (kg) X mg/kg bdy. wt.
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2.

Uric Acid Determinations by Colorimetric Method*
Blood :

O,D 1 Unk 1

X Cone. Std.= Cone. Unk.

O.D. Std.
Liver:

O,D, Unk,

X Cone. Std. X c.f. = Cone. Unk.

O. D. Std.
Correction Factor:
c.f.

=

wt, of Homogenate (Liver+

H

20

Wt. of Liver
I

* o.o.

=

Optical Density

Unk.

=

Unknown

Std.

Standard

Cone.

=
=

c.f.

=

Correction Factor (necessary for the adjustment of diluted liver uric acid concentrations
which were linear to 20 mg%)

Concentration

CHAPTER IV
RESULTS AND DISCUSSION

Data were collected on a series of three experiments
designed to determine the relationship between 6-MP toxicity
and uric acid synthesis in male White Leghorn chicks .

All

treated chicks received 6-MP by oral administration daily
at an average dosage level of 1800 mg/kg bdy wt/day.

Tox-

icity studies were based on macroscopic manifestations.

Uric

acid concentrations were determined by colorimetric analysis
of the blood and liver.
Figure l.illustrates the effect of 6-MP on the growth
rate of the chicks .

Five day old chicks receiving 6-MP for

a period of 10-12 days (LD50) experienced a suppression in
weight gain.

Immediately following cessation of treatment

{post-treatment period), treated animals showed a rapid increase in growth rate.

Weight gains of control and treated

chicks were equivalent from 6-8 days following cessation of
treatment.
The suppression of weight gain of chicks treated with
6-MP observed in these experiments confirms the postulation
of Goodhart (1955) .

It was stated that anti.metabolites are

compounds which are antagonistic to metabolites of physiologic importance.

More specifically, an antimetabolite is

sufficiently similar in structure to an essential metabolite
to tend to replace it in biological systems, thus causing
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Fig. 1.

Relationship between 6-MP treatment (1-12 days)

and growth rate of male White Leghorn chicles.
ment period of 8 days is also shown.
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a conditioned deficiency of the metabolite necessacy for
normal growth.
The relationship between weight gain suppression and
toxicity is supported by Woolley (1947), who reported that
antagonists (antimetabolites) are competitive with the naturally occurring substances, competing for essential enzyme
systems with which the metabolite normally reacts.

The

property of inactivating enzyme systems is a common one among cellular poisons.
The daily dosage levels of 6-MP administration are
shown in Figure 2A.

The LD50 of 6-MP in White Leghorn cock-

erels was detennined to be 1800 mg/kg bdy wt/day.

Daily

dosages of 6-MP administered orally in gelatin capsules are
recorded in Figure 2B.
Figures 3A and 3B illustrate the effect of 6-MP on
uric acid concentrations in the serum and liver of chicks,
respectively.

All values were analyzed statistically for

significance of differences .
Following a five day treatment period, uric acid determinations were 9.04!0.12 mg% and 9.73?0.05 mg% serum uric
acid for control and treated chicks, respectively.

The

differences between these values were highly significant
(P=.01).

There was no significant difference between liver

values of 127.36!10.88 mg% for controls and 138.20!7. 82 mg%
for treated chicks, respectively.

lt is suggested that
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Fig. 2-A.

Dosage level of 6-MP administered daily.

Fig. 2-B.

Daily dosages of 6-MP orally administered.
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Fig. 3-A.

Effects of 6-MP on serum uric acid concentration

following five and twelve day treatment periods and eight
days post-treatment.

Fig. 3-B.

Effects of 6-NP on liver uric acid concentration

following five and twelve day treatment periods and eight
days post-treatment.
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since the liver is the site for the synthesis of uric acid,
which is readily conveyed to the excretory organs via the
blood, an increase in sert.nn uric acid concentration is logical at an early stage of treatment.
After a 10-12 day treatment period of LD50 was attained
in each of the three experiments conducted.

Results of these

analyses are presented in Figures 3A and 3B.

Sert.nn uric acid

values, 8.05!0.38 mg% and 12.61?0.61 mg% for control and treated chicks, respectively, and liver uric acid values,
120.37!2.53 mg% and 163.38!0.24 mg% for control and treated
chicks, respectively, were directly correlated.

Differences

in uric acid values between control and treated chicks, in
both the serum and liver, were highly significant (P=.01).
The results obtained with chicks substantiate
findings of other investigations.

the

According to Gerbrandy,

(1958 ); Sandberg et al., (1956); Krakoff et al., (1961);
Watkin and Silver, (1958), very large quantities of uric acid
are excreted during treatment of leukemia with X-rays, steroids and antimetabolites.

Krakoff et al., (1961), stated

that not all antimetabolites will cause a rise in uric acid
excretion; folic acid antagonists block purine synthesis at
a stage prior to that of uric acid formation and their administration is followed by a fall rather than a rise in urinary
uric acid.
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Uric acid analyses of the serum and liver, 6-8 days
post treatment, showed no signicicant differences between
control and treated chicks.

Figures 3A and 3B illustrate

values determined for serum (controls 8.81?0. 17 mg%; treated 9 . 16%0.24 mg%) and liver (controls 135.59±2.38 mg%;
treated 136.27!4.62 mg%), respectively.
The results of toxicity studies of chicks treated
with 6-MP for a period of 10-12 days are presented in Table
l.

Weight suppression, hepatic necrosis, gastro-intestinal

disturbances (congestion, lesions in the epithelial lining,
etc.), feces and liver discoloration and high mortality
rate from 7-12 days of treatment were manifested in all
three experiments conducted.

In contrast, none of the above

mentioned symptoms were observed in the control groups.
The most severe toxic effects and highest uric acid
concentrations in the serum and liver of chicks t~eated with
1800 mg/kg bdy wt/day of 6-MP were evidenced in LD50, 10-12
days after treatment.

It would then appear that here exists

a direct relationship between 6-MP toxicity and uric acid
synthesis in the chick.

